Investigator Oversight Section
ICH E6(R3) makes investigator oversight a distinct responsibility even when trial-related activities are delegated. The expected level of oversight should reflect the nature of the delegated work, participant risk, and importance of the data.
An Investigator Oversight section explains how the investigator will supervise delegated trial activities while retaining responsibility for participant protection and reliable data.
Key details
Important caveats
Scope Boundary
Do not merge investigator oversight with sponsor monitoring. Roles vary by delegation, site organization, service-provider arrangements, local requirements, and trial risk.
Further guidance
Content
Describe oversight responsibilities, communication or review mechanisms, escalation of material issues, and how oversight is proportionate to the significance and risk of delegated activities.
Purpose
Clarify how investigator responsibility is exercised when work is distributed among staff or service providers.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
- E6(R3) Good Clinical Practice Guidance for Industry — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current ICH E6(R3) GCP guidance on investigator oversight, training/delegation, participant withdrawal, investigational-product accountability, site close-out, essential records, and insurance/indemnification